论文部分内容阅读
镭223二氯化物(Radium Ra 223 dichloride)是由拜耳(Bayer)公司开发的一种治疗有症状骨转移(symptomatic bone metastases)及无已知内脏转移(no known visceral metastatic disease)的去势抵抗性前列腺癌(castration-resistant prostate cancer,CRPC)的药物,于2013年5月15日由美国FDA批准上市[1],商品名为Xofigo。分子式:223RaCl2;分子量:293.924;CAS登记号:444811-40-9。前列腺癌是男性生殖系统最常见的恶性肿瘤之一[2],居男性癌症死亡的第二位。体内转移性癌症影响的最常见部位是骨骼,前列腺癌的骨转移尤为普遍。转
Radium Ra 223 dichloride is a castration-resistant drug developed by the Bayer company for the treatment of symptomatic bone metastases and no known visceral metastatic disease Prostate cancer (castration-resistant prostate cancer, CRPC) drugs, approved by the US FDA on May 15, 2013 [1], under the trade name Xofigo. Molecular formula: 223 RaCl2; molecular weight: 293.924; CAS registry number: 444811-40-9. Prostate cancer is one of the most common malignant tumors of the male reproductive system [2], ranking second in male cancer deaths. The most common site of metastatic cancer in vivo is bone, which is particularly prevalent in bone metastases from prostate cancer. turn